Related Experiment Video
Updated: Feb 3, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Potential Uses of Sacubitril/Valsartan: Need for Data on Efficacy and Safety
Fabien Huet1,2, Mariama Akodad1,2, Eran Kalmanovitch1
1Département de Cardiologie, Hôpital Arnaud de Villeneuve, CHU de Montpellier, UFR de Médecine, Université Montpellier 1, 371, avenue du Doyen Gaston Giraud, 34295, Montpellier Cedex 5, France.
Insights
Sacubitril/valsartan (SV) shows promise beyond reduced ejection fraction heart failure, potentially benefiting preserved ejection fraction heart failure and chronic kidney disease. Further research is needed to address uncertainties for its widespread clinical use.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Nephrology
Background:
- Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are established treatments for heart failure with reduced ejection fraction.
- Emerging evidence suggests potential benefits of sacubitril/valsartan (SV) in other cardiovascular and renal conditions.
Purpose of the Study:
- To review the emerging therapeutic applications of sacubitril/valsartan (SV) in heart failure with preserved ejection fraction and chronic kidney disease.
- To discuss the potential limitations and challenges of implementing SV in routine clinical practice.
Main Methods:
- Literature review of recent studies on sacubitril/valsartan (SV) efficacy in alternative indications.
- Analysis of potential clinical pitfalls and areas of uncertainty regarding SV use.
Main Results:
- Sacubitril/valsartan (SV) demonstrates promising efficacy in heart failure with preserved ejection fraction and chronic kidney disease.
- Cognitive uncertainties and practical challenges may limit the immediate widespread adoption of SV in routine care.
Conclusions:
- Sacubitril/valsartan (SV) represents a potential therapeutic advancement for conditions beyond its initial indication.
- Addressing current uncertainties is crucial for optimizing the clinical utility of SV in diverse patient populations.
Abstract:
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have been the cornerstone for the treatment of heart failure (HF) with reduced ejection fraction for decades. According to recent and promising studies, sacubitril/valsartan (SV) might be efficient in alternative indications in the area of HF with preserved left ventricular ejection fraction, chronic kidney disease, and so on. This review briefly summarizes these promising therapeutic options regarding SV and the potential limits and pitfalls for its use in routine practice (due to cognitive uncertainties).
More Related Videos
Related Concept Videos
Survey Safety
Self-Efficacy
Household Wiring And Electrical Safety
Potential Energy
Chemical bonds that form attractive forces between atoms also contain potential energy, called chemical energy. When a chemical reaction...
How Data are Classified: Categorical Data
Data are classified based on whether they are measurable or not. Categorical data cannot be measured; instead, it can be divided into categories. For example, if Y denotes a person's party affiliation, some examples of Y include...
How Data are Classified: Numerical Data
Quantitative data may be either discrete or continuous. All quantitative data that take on only specific numerical...

